Having successfully listed our shares on the Tokyo Stock Exchange Growth Market, Veritas In Silico Inc. (“the Company”) will celebrate its 10th anniversary this coming November. The Company firmly believes that this significant milestone would not have been possible without the unwavering support of its shareholders since its founding, and expresses its sincere and heartfelt gratitude.
The Company’s corporate philosophy, driven by its proprietary mRNA-targeted drug discovery platform, aibVIS, is to “realize and foster a hope-filled and compassionate society where patients suffering from any disease will not have to abandon hope due to a lack of treatment, nor lament the unavailability of optimal care.[SN1.1]”
Since its establishment, the Company has consistently dedicated itself to in-house research and development. It is also currently collaborating with several pharmaceutical companies to advance small-molecule drug discovery. Since its IPO, the Company has actively engaged to build its own pipelines as well. This commitment is a testament to its firm determination to contribute sustainably to society as a specialty pharmaceutical company in the future.
Looking back, the Company did not hold a single patent when it was established. Although it has since expanded its business and achieved a public listing, the Company keenly recognizes that it is still in a crucial phase in advancing its technological capabilities. Spurred by this renewed mindset, all its executives and employees were greatly motivated, leading to the filing of six new patent applications last fiscal year related to drug delivery systems and AI. The Company is committed to achieve breakthroughs not only through AI but also through a variety of practical technologies.
The Company sincerely asks for your continued and even greater support as it embarks on this journey forward.
Shingo NAKAMURA
Representative Director and CEO
Shingo Nakamura
Representative Director, Founder and CEO